NEW YORK, January 13, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Alere Inc. (NYSE: ALR), ARCA biopharma, Inc. (NASDAQ: ABIO), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Receptos, Inc. (NASDAQ: RCPT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Alere Inc. Research Report
On January 8, 2014, Alere Inc.'s (Alere) stock advanced 6.18%, ending the day at $38.49. Over the previous three trading sessions, shares of Alere increased 6.86%, compared to the S&P 500 which gained 0.33% during the same period. The Full Research Report on Alere Inc.- including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
ARCA biopharma, Inc. Research Report
On January 8, 2014, ARCA biopharma, Inc. (ARCA) announced that Laboratory Corporation of America informed the Company that the US Food and Drug Administration (FDA) has accepted LabCorp's Investigational Device Exemption (IDE) application for the planned companion diagnostic test for GencaroTM (bucindolol hydrochloride). According to the Company, the IDE enables the companion diagnostic test to be used in the planned GENETIC-AF clinical trial. ARCA reported that its Gencaro Investigational New Drug (IND) application for AF has been accepted by FDA and is active. The Company added that LabCorp will provide the patient genetic testing for ARCA's GENETIC-AF clinical trial of Gencaro, which is expected to commence patient enrollment in Q1 2014. The Full Research Report on ARCA biopharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Achillion Pharmaceuticals, Inc. Research Report
On January 8, 2014, Achillion Pharmaceuticals, Inc.'s (Achillion) stock advanced 13.29%, ending the day at $3.75. Over the previous three trading sessions, shares of Achillion increased 8.07%, compared to the Nasdaq Composite which advanced 0.82% during the same period. The Full Research Report on Achillion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Idenix Pharmaceuticals Inc. Research Report
On January 6, 2014, Idenix Pharmaceuticals Inc. (Idenix) announced the appointment of Jacques Dumas, Ph.D., as Executive Vice President and Chief Scientific Officer, effective January 20, 2014. Ron Renaud, President and CEO of Idenix stated, "Dr. Dumas brings a good complement of deep chemistry expertise and overall business strategy to the Idenix team. His knowledge and leadership will be important as we continue to conduct our nucleotide prodrug discovery work in HCV as well as explore potential therapeutic areas for which we can apply our chemistry expertise. Additionally, as a native of France and a resident of the Boston area, Jacques is an ideal fit to direct our talented research teams in both Cambridge and Montpellier." The Company added that Dr. Dumas was AstraZeneca plc's Vice President and Head of Strategy, Infection Innovative Medicines since December 2010. The Full Research Report on Idenix Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Receptos, Inc. Research Report
On January 6, 2014, Receptos, Inc. (Receptos) announced that it has enrolled the first patients in the Phase 3 portion of RADIANCE, its Phase 2/3 study of RPC1063 in relapsing multiple sclerosis (RMS). According to Receptos, the RADIANCE Phase 2/3 study was designed to accelerate the RMS clinical development program for RPC1063 by allowing progression into Phase 3 in a rapid fashion and removing the delay between the completion of a Phase 2 study and the initiation of a subsequent Phase 3 study. The Company stated that the second Phase 3 study is intended to commence after the top-line results of the Phase 2 portion of the RADIANCE study are announced, which are expected in mid-2014. Faheem Hasnain, President and CEO of Receptos, commented, "Our initiation of Phase 3 positions RPC1063 as the potential next-to-market sphingosine 1-phosphate 1 receptor (S1P1R) modulator for the treatment of relapsing multiple sclerosis. Since the founding of Receptos in 2009, we have made rapid progress in the development of RPC1063, which we believe may represent a best-in-class molecule in the S1P1R modulator class." The Full Research Report on Receptos, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner